360 NEWS360 NEWS
Home / Business

Biocon’s Pebrilzo becomes first biosimilar approved under EMA’s tailored clinical pathway

The approval marks a regulatory milestone for Biocon and expands its portfolio of oncology biosimilars approved in Europe and the United States.

Published
Original News Source The Hindu BusinessLine
Content & Media Rights The Hindu BusinessLine
Editorial Publisher 360 NEWS (Independent Media)
Biocon’s Pebrilzo becomes first biosimilar approved under EMA’s tailored clinical pathway
Photo / Source: The Hindu BusinessLine
The approval marks a regulatory milestone for Biocon and expands its portfolio of oncology biosimilars approved in Europe and the United States.

Editorial & Syndication Notice: This story has been syndicated or published by 360 NEWS in accordance with verified fair-use, official press dissemination, and original attribution protocols. All trademarks, photos, and referenced quotes remain the property of their respective owners. For editorial corrections, press inquiries, or rights notices, contact [email protected].